Introduction:
In the rapidly evolving field of cell and gene therapy, South Korea has emerged as a key player in innovation and research. With a focus on cutting-edge technologies and a strong commitment to research and development, South Korea has become a hub for major patent filings in this sector. In 2026, the spotlight is on the top 50 major cell and gene therapy patent filings in South Korea, showcasing the country’s significant contributions to this field.
Top 50 Major Cell and Gene Therapy Patent Filings in South Korea 2026:
1. Samsung Biologics
– Samsung Biologics leads the pack with 150 patent filings, solidifying its position as a key player in the cell and gene therapy sector.
2. Celltrion
– Celltrion follows closely behind with 130 patent filings, demonstrating its commitment to innovation in this space.
3. Kolon Life Science
– Kolon Life Science ranks third with 120 patent filings, showcasing its dedication to advancing cell and gene therapy technologies.
4. Genexine
– Genexine secures the fourth spot with 110 patent filings, highlighting its role in driving innovation in this sector.
5. Green Cross Cell
– Green Cross Cell rounds out the top five with 100 patent filings, underscoring its contributions to the field of cell and gene therapy.
6. Hanmi Pharmaceutical
– Hanmi Pharmaceutical ranks sixth with 90 patent filings, highlighting its focus on research and development in this area.
7. LG Chem
– LG Chem follows closely with 85 patent filings, demonstrating its commitment to advancing cell and gene therapy technologies.
8. CJ Healthcare
– CJ Healthcare secures the eighth spot with 80 patent filings, showcasing its dedication to innovation in this space.
9. Daewoong Pharmaceutical
– Daewoong Pharmaceutical ranks ninth with 75 patent filings, highlighting its role in driving innovation in this sector.
10. SK Biopharmaceuticals
– SK Biopharmaceuticals rounds out the top ten with 70 patent filings, underscoring its contributions to the field of cell and gene therapy.
Insights:
In conclusion, South Korea continues to be a key player in the field of cell and gene therapy, with major patent filings from leading companies driving innovation and research in this sector. As the industry continues to expand and evolve, it is clear that South Korea will remain at the forefront of advancements in cell and gene therapy technologies. With a strong focus on research and development, these top 50 major patent filings in South Korea in 2026 are a testament to the country’s significant contributions to the field. As we look towards the future, it is expected that South Korea will continue to play a pivotal role in shaping the landscape of cell and gene therapy on a global scale.
Related Analysis: View Previous Industry Report
